Caplight Directory>Companies>Resolution Therapeutics-preview>Resolution-tx


Resolution Therapeutics

Resolution Therapeutics

Private
EdinburghHealthcare & Life Scienceshttps://resolution-tx.com

Last Round

Series B

Oct 3, 2024

Total Funding Raised

$132.1M

Company Overview

Resolution Therapeutics is a biotechnology company developing regenerative macrophage cell therapies to treat inflammatory and fibrotic diseases, with an initial focus on end-stage liver disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

macrophage cell therapyengineered macrophagesregenerative medicineend-stage liver diseasecell therapyautologous cell therapycirrhosis treatmentliver transplant alternativeliver fibrosisliver repairfibrotic diseasesinflammatory diseasesallogeneic cell therapyoff-the-shelf cell therapyiPSC-derived macrophagesiPSCclinical-stage biopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Resolution Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Resolution Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BOct 3, 2024
Series A ExtensionApr 5, 2022
Series ADec 2, 2020
View all Funding Rounds

Key People

Founding team and executive leadership

Lucy Singah

Chief Financial Officer

Executive Team

Resolution Therapeutics Investors

Notable investors and investment history

InvestorRounds
SynconaSeries B
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 11, 2025

    Daniel Kennedy appointed as the new Chief Business Officer.

  • Sep 11, 2025

    Lucy Singah appointed as the new CFO.

View all signals

Resolution Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Resolution Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Resolution Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersEdinburgh
Employee Range72
Year Founded2017
Last FundingOct 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.